OBJECTIVES:

• Determine the disease-free and overall survival of patients with acute myelogenous leukemia in first remission treated with busulfan and cyclophosphamide plus iodine I 131 monoclonal antibody BC8 followed by HLA identical related bone marrow transplantation.
• Determine the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter study.

Patients receive a test dose of iodine I 131 monoclonal antibody BC8 (I131 MOAB BC8) IV, then about 2 weeks later, on day -13, a therapeutic dose of I131 MOAB BC8 IV is administered. Patients then receive oral busulfan every 6 hours on days -7 to -4 (16 doses) and cyclophosphamide IV on days -3 and -2. Donor bone marrow is infused on day 0.

Patients are followed at 6, 9, and 12 months, then every 6 months for 1 year, then annually thereafter.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

DISEASE CHARACTERISTICS:

• Acute myelogenous leukemia in first remission
• No prior or concurrent CNS involvement by leukemia
• Genotypically or phenotypically HLA matched family member available as donor

PATIENT CHARACTERISTICS:

Age

• 16 to 55

Performance status

• Not specified

Life expectancy

• More than 60 days

Hematopoietic

• Not specified

Hepatic

• Bilirubin less than 1.5 mg/dL
• AST no greater than 1.5 times upper limit of normal
• No current hepatitis
• No high risk for developing veno-occlusive disease of the liver

Renal

• Creatinine less than 2.0 mg/dL

Other

• HIV negative
• No major infection
• No perceived inability to tolerate study procedures, particularly treatment in radiation isolation
• No circulating antibody to mouse immunoglobulin
• Not pregnant or nursing
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• No prior radiotherapy to maximum tolerated levels to any normal organ

Surgery

• Not specified